The Latest Cardiac and Vascular News
OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide…
ATLANTA, Oct. 23, 2025 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the…
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com/. About Heartflow’s Technology and ResearchBacked by ACC/AHA guidelines and over 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly 500,000 patients worldwide. Our continuous innovation is driven by an unmatched proprietary data pipeline built from over 110 million annotated CTA images. Heartflow’s AI-driven solutions have been extensively validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%. Heartflow’s integrated workflow delivers analysis instantly upon order, enabling clinicians to move from diagnosis to decision without delay. To uphold the highest security and patient-data integrity standards, Heartflow fully complies with leading global security regulations, including HITRUST, SOC2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001. About Heartflow, Inc.Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com. Investor ContactNick Laudiconlaudico@heartflow.com Media ContactElliot Levyelevy@heartflow.com
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that two-year results from an analysis of early clinical studies evaluating the AccuCinch® Transcatheter Left Ventricular Restoration System were published in Structural Heart. The findings demonstrate that reverse remodeling achieved […]
PARIS & BOSTON–(BUSINESS WIRE)–Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, today announced the appointment of Jonathan Freeman, PhD, as Chairman of its Board of Directors. This marks a key milestone in the company’s evolution, reinforcing its ambition to set new frontiers in the treatment of […]
MINNETONKA, Minn.–(BUSINESS WIRE)–AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed […]
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and well-tolerated, with no increase in serious adverse events versus placebo. Scp776 leverages Silver Creek’s proprietary […]
Company to host educational symposium and demonstrate High-Frequency OCT Imaging System SUDBURY, Mass., Oct. 23, 2025 /PRNewswire/ — Gentuity LLC, a Massachusetts-based medical technology company specializing in next-generation intravascular imaging devices, today announced their…
An investigational, suture-based large bore closure device intended to deliver fast and reliable vascular closure MENLO PARK, Calif., Oct. 23, 2025 /PRNewswire/ — Cordis-X today announced that it has enrolled the first 25 patients in the FASTEN trial in pursuit of CE mark for Ladera…
SANTA CRUZ, Calif., Oct. 23, 2025 /PRNewswire/ — Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient enrollment in its Protect the Head to Head (ProtectH2H) Clinical Trial, a pivotal…
